Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29345819 | 0.81 | CHRM2 (0.34) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL29343999 | 0.80 | SSTR4 (0.36) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL29344015 | 0.80 | CYP2B6 (0.35) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL31245736 | 0.80 | CYP2B6 (0.35) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL29937033 | 0.80 | SSTR4 (0.36) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL29344003 | 0.78 | OPRK1 (0.34) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL26981396 | 0.75 | OPRK1 (0.40) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL29344018 | 0.74 | SSTR4 (0.40) | OPRK1KCNH2CHRM2CHRM1CHRM3 | |
| SCHEMBL29936884 | 0.71 | SSTR4 (0.40) | OPRK1KCNH2CYP2B6SSTR4 | |
| SCHEMBL24894678 | 0.71 | JAK1 (0.45) | OPRK1KCNH2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | OPRK1 4635/4885KCNH2 3893/4885CHRM2 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.